Myasthenia Gravis Disease Treatment Market Size & Share Global Analysis Report, 2023-2032

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2023 - 2032

Published Date:Nov-2023
Pages: 116
Format: PDF
Report ID: PM4026
Base Year: 2022
Historical Data: 2019-2021

Report Summary

The global myasthenia gravis disease treatment market was valued at USD 1.19 billion in 2022 and is expected to grow at a CAGR of 6.9% during the forecast period.

Myasthenia gravis is a persistent autoimmune neuromuscular condition that disrupts the transmission of signals between nerves and muscles. This disruption results in muscle weakness and exhaustion, predominantly impacting voluntary muscles responsible for activities such as swallowing, speech, and the control of facial expressions.

Myasthenia Gravis Disease Treatment Market Size

To Understand More About this Research: Request a Free Sample Report

The market for treating Myasthenia Gravis (MG) has experienced consistent growth in recent times, propelled by various factors. The rise in diagnostic rates, enhanced comprehension of the disease, and advancements in treatment choices have collectively fostered the market's expansion. Moreover, pharmaceutical enterprises have devoted resources to research and development, aiming to unveil innovative therapies characterized by enhanced effectiveness and reduced side effects. The global MG treatment market is anticipated to sustain its growth trajectory, driven by the ongoing demand for treatments that are both more efficacious and safer, notably with the advent of biologics and targeted therapies.

Myasthenia gravis treatment focuses on symptom management, muscle function improvement, and immune response suppression. It typically involves acetylcholinesterase inhibitors (e.g., pyridostigmine) to boost nerve-muscle communication, immunosuppressive medications (e.g., corticosteroids, azathioprine) to control the immune system, and, in severe cases or when medications are insufficient, therapies like plasma exchange and IVIG. Thymectomy may be advised for some patients, as the thymus is implicated in MG development.

The COVID-19 pandemic has a significant impact on the Myasthenia Gravis (MG) disease market. Myasthenia Gravis is an autoimmune neuromuscular disorder that affects the muscles and can lead to weakness and fatigue. The pandemic brought both challenges and opportunities to this market. On the one hand, the healthcare system's focus and resources were largely diverted towards managing and treating COVID-19 patients, leading to delays in the diagnosis and treatment of MG patients. Elective procedures and non-urgent medical appointments were often postponed, affecting MG patients who required regular medical interventions.

On the other hand, the pandemic accelerated the adoption of telemedicine and remote monitoring, which proved to be a valuable tool for MG patients to consult with their healthcare providers without risking exposure to the virus. Additionally, the pharmaceutical industry continued to develop new therapies for MG, providing hope for improved treatment options. Overall, the MG disease market saw disruptions but also witnessed innovation and adaptation in response to the challenges posed by the COVID-19 pandemic.

Industry Dynamics

Growth Drivers

Improvement in therapies and treatment options across the Globe will Facilitate Market Growth

The market growth of myasthenia gravis disease during the forecast period is primarily driven by the improvement in therapies and treatment options across the globe.

Myasthenia gravis (MG) results from antibodies disrupting acetylcholine receptors at nerve-muscle junctions, causing muscle weakness, especially in facial, swallowing, and limb muscles. Treatment focuses on symptom management, muscle function improvement, and immune system suppression. Options include acetylcholinesterase inhibitors (e.g., pyridostigmine), immunosuppressive drugs (like corticosteroids and azathioprine), and therapies like plasma exchange, intravenous immunoglobulin (IVIG), and thymectomy for select cases.

The myasthenia gravis disease treatment market is growing due to increased MG prevalence, better awareness and diagnostics, advanced treatment options, and expanding healthcare infrastructure, particularly in emerging markets. Pharmaceutical companies are investing in innovative therapies, including biologics, monoclonal antibodies, and targeted treatments, contributing to market growth.

Report Segmentation

The market is primarily segmented based on drug class, diagnosis, treatment, distribution channel, and region.

By Drug Class

By Diagnosis

By Treatment

By Distribution Channel

By Region

IVIg
Monoclonal Antibodies
Immunosuppressants
Cholinesterase Inhibitors
Corticosteroids

Blood Tests
Electrodiagnosis
Edrophonium Test

Surgery
Medication
HSCT

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

North America (U.S., Canada)
Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Drug Class Analysis

The IVIg segment held the largest revenue share in 2022

In 2022, the IVIg segment held the largest revenue share. Intravenous Immunoglobulin (IVIg) therapy involves administering immunoglobulin antibodies sourced from healthy donors intravenously. This medical procedure has been shown to effectively manage symptoms of Myasthenia Gravis (MG) by temporarily regulating the immune system. One of the key benefits of IVIg therapy is its ability to enhance muscle strength and overall neuromuscular function rapidly, especially during myasthenic crises or exacerbation periods. In such critical scenarios, IVIg therapy has become the gold standard, providing quick relief and stabilizing patients' conditions.

Moreover, IVIg is a safer alternative to other immunosuppressive medications since it avoids the long-term risks associated with extended use of steroids and other immunosuppressants. The expansion of healthcare infrastructure and improved accessibility to specialized care centers have also played a pivotal role in the growing utilization of IVIg therapy for the treatment of MG.

By Distribution Channel Analysis

The hospital pharmacies segment accounted for the highest market share in 2022

The hospital segment accounted for the highest market share in 2022, Hospital pharmacies play a crucial role in managing Myasthenia Gravis (MG) by dispensing and administering various medications, including immunosuppressants, acetylcholinesterase inhibitors, and intravenous immunoglobulin (IVIg). As the prevalence of MG continues to increase, more patients are seeking specialized medical attention in hospital settings. This has led to an expansion of the pool of diagnosed patients, who are then referred to hospital-based healthcare providers with expertise in tailored MG treatment. This influx of patients has resulted in an increased demand for medications specific to MG within hospital pharmacies.

The territory of MG treatment is also evolving, with advancements in therapeutic modalities and the introduction of novel medications, which offer more options for MG patients. As a result, hospital pharmacies are becoming increasingly central to the holistic care and management of MG patients, ensuring sustained growth and development.

Regional Insights

North America dominated the largest market in 2022

In 2022, North America dominated the largest market contributor in the myasthenia gravis disease market, with the United States foremost in revenue. Myasthenia gravis (MG) is highly prevalent in North America, making it a dominant region in the treatment market. The region's well-established healthcare infrastructure enables the diagnosis and treatment of a large number of MG cases, attracting pharmaceutical companies and researchers. Additionally, the robust healthcare reimbursement system covers many expensive MG treatments, making them more accessible to patients and encouraging timely treatment. North America's leading pharmaceutical and biotechnology companies have played a vital role in advancing MG treatments.

Asia Pacific is anticipated for the fastest growth in myasthenia gravis disease market. The expansion of the market can be attributed to several key factors, with a prominent emphasis on the escalating efforts undertaken by both governmental and private entities. These concerted endeavors are primarily directed towards the development and dissemination of efficacious treatments for neuromuscular disorders. Additionally, the market's growth trajectory is further propelled by a rising tide of awareness within the populace concerning neuromuscular ailments, spurred on by educational campaigns and information dissemination initiatives. Furthermore, the healthcare sector in this particular geographic area has witnessed substantial enhancements and innovations, contributing significantly to the overall growth of the market for myasthenia gravis disease treatments.

Key Market Players & Competitive Insights

The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.

Some of the major players operating in the global market include:

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
Grifols, S.A.
Mylan N.V. (now part of Viatris Inc.)
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Roche Holdings AG (including its subsidiary, Genentech)
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Recent Developments

In December 2021, the global immunology firm argenx, which had been dedicated to developing a therapy for generalized myasthenia gravis known as "VYVGART," made a significant announcement. They revealed that the U.S. Food and Drug Administration (FDA) had approved for the utilization of VYVGART in the treatment of generalized myasthenia gravis (gMG) among adult patients.
In In March 2021, Horizon Therapeutics plc acquired Viela Bio, Inc. in order to enhance the company's range of offerings, expand its pipeline, and strengthen its focus on medications for rare diseases.

Myasthenia Gravis Disease Treatment Market Report Scope

Report Attributes	Details
Market size value in 2023	USD 1.27 billion
Revenue forecast in 2032	USD 2.32 billion
CAGR	6.9% from 2023 – 2032
Base year	2022
Historical data	2019 – 2021
Forecast period	2023 – 2032
Quantitative units	Revenue in USD billion and CAGR from 2023 to 2032
Segments Covered	By Drug Class, By Diagnosis, By Treatment, By Distribution Channel, By Region
Regional scope	North America, Europe, Asia Pacific, Latin America; Middle East & Africa
Customization	Report customization as per your requirements with respect to countries, region and segmentation.

1. Introduction
              1.1. Report Description
                    1.1.1. Objectives of the Study
                    1.1.2. Market Scope
                    1.1.3. Assumptions
              1.2. Stakeholders
2. Executive Summary
              2.1. Market Highlights
3. Research Methodology
              3.1. Overview
                    3.1.1. Data Mining
              3.2. Data Sources
                    3.2.1. Primary Sources
                    3.2.2. Secondary Sources
4. Global Myasthenia Gravis Disease Treatment Market Insights
              4.1. Myasthenia Gravis Disease Treatment – Industry Snapshot
              4.2. Myasthenia Gravis Disease Treatment Market Dynamics
                    4.2.1. Drivers and Opportunities
                            4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
                            4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
                    4.2.2. Restraints and Challenges
                            4.2.2.1. High treatment cost will hamper on the market growth
              4.3. Porter’s Five Forces Analysis
                    4.3.1. Bargaining Power of Suppliers (Moderate)
                    4.3.2. Threats of New Entrants: (Low)
                    4.3.3. Bargaining Power of Buyers (Moderate)
                    4.3.4. Threat of Substitute (Moderate)
                    4.3.5. Rivalry among existing firms (High)
              4.4. PESTLE Analysis
              4.5. Myasthenia Gravis Disease Treatment Industry Trends
              4.6. Value Chain Analysis
              4.7. COVID-19 Impact Analysis
5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class
              5.1. Key Findings
              5.2. Introduction
                    5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
              5.3. IVIg
                    5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
              5.4. Monoclonal Antibodies
                    5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
              5.5. Immunosuppressants
                    5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
              5.6. Cholinesterase Inhibitors
                    5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  5.7. Corticosteroids
                    5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis
              6.1. Key Findings
              6.2. Introduction
                    6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
              6.3. Blood Tests
                    6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
              6.4. Electrodiagnosis
                    6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
              6.5. Edrophonium Test
                    6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)
7. Global Myasthenia Gravis Disease Treatment Market, by Treatment
              7.1. Key Findings
              7.2. Introduction
                    7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
              7.3. Surgery
                    7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
              7.4. Medication
                    7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
              7.5. HSCT
                    7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)
8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel
              8.1. Key Findings
              8.2. Introduction
                    8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
              8.3. Online Pharmacies
                    8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
              8.4. Hospital Pharmacies
                    8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
  8.5. Retail Pharmacies
                    8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
9. Global Myasthenia Gravis Disease Treatment Market, by Geography
              9.1. Key findings
              9.2. Introduction
                    9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
              9.3. Myasthenia Gravis Disease Treatment Market – North America
                    9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                    9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                    9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                    9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.3.5. Myasthenia Gravis Disease Treatment Market – U.S.
                                          9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                          9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                                          9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                                          9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.3.6. Myasthenia Gravis Disease Treatment Market – Canada
                            9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
              9.4. Myasthenia Gravis Disease Treatment Market – Europe
                    9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                    9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                    9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                    9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.5. Myasthenia Gravis Disease Treatment Market – UK
                            9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.6. Myasthenia Gravis Disease Treatment Market – France
                            9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.7. Myasthenia Gravis Disease Treatment Market – Germany
                            9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.8. Myasthenia Gravis Disease Treatment Market – Italy
                            9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.9. Myasthenia Gravis Disease Treatment Market – Spain
                            9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.10. Myasthenia Gravis Disease Treatment Market – Netherlands
                            9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.4.11. Myasthenia Gravis Disease Treatment Market – Russia
                            9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
              9.5. Myasthenia Gravis Disease Treatment Market – Asia Pacific
                    9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                    9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                    9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                    9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.5. Myasthenia Gravis Disease Treatment Market – China
                            9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.6. Myasthenia Gravis Disease Treatment Market – India
                            9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.7. Myasthenia Gravis Disease Treatment Market – Japan
                            9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.8. Myasthenia Gravis Disease Treatment Market – Malaysia
                            9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.9. Myasthenia Gravis Disease Treatment Market – Indonesia
                            9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                                  9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.5.10. Myasthenia Gravis Disease Treatment Market – South Korea
                            9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
              9.6. Myasthenia Gravis Disease Treatment Market – Middle East & Africa
                    9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                    9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                    9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                    9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.6.5. Myasthenia Gravis Disease Treatment Market – Saudi Arabia
                            9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.6.6. Myasthenia Gravis Disease Treatment Market – South Africa
                            9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.6.7. Myasthenia Gravis Disease Treatment Market – Israel
                            9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.6.8. Myasthenia Gravis Disease Treatment Market – UAE
                            9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
              9.7. Myasthenia Gravis Disease Treatment Market – Latin America
                    9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                    9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                    9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                    9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.7.5. Myasthenia Gravis Disease Treatment Market – Mexico
                            9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.7.6. Myasthenia Gravis Disease Treatment Market – Brazil
                            9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
                    9.7.7. Myasthenia Gravis Disease Treatment Market – Argentina
                            9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
                            9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
                            9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
                            9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
10. Competitive Landscape
              10.1. Expansion and Acquisition Analysis
                    10.1.1. Expansion
                    10.1.2. Acquisitions
              10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
              11.1. AbbVie Inc.
                    11.1.1. Company Overview
                    11.1.2. Financial Performance
                    11.1.3. Product Benchmarking
                    11.1.4. Recent Development
              11.2. Alexion Pharmaceuticals, Inc.
                    11.2.1. Company Overview
                    11.2.2. Financial Performance
                    11.2.3. Product Benchmarking
                    11.2.4. Recent Development
              11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
                    11.3.1. Company Overview
                    11.3.2. Financial Performance
                    11.3.3. Product Benchmarking
                    11.3.4. Recent Development
              11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
                    11.4.1. Company Overview
                    11.4.2. Financial Performance
                    11.4.3. Product Benchmarking
                    11.4.4. Recent Development
              11.5. Grifols, S.A.
                    11.5.1. Company Overview
                    11.5.2. Financial Performance
                    11.5.3. Product Benchmarking
                    11.5.4. Recent Development
              11.6. Mylan N.V. (now part of Viatris Inc.)
                    11.6.1. Company Overview
                    11.6.2. Financial Performance
                    11.6.3. Product Benchmarking
                    11.6.4. Recent Development
              11.7. Novartis AG
                    11.7.1. Company Overview
                    11.7.2. Financial Performance
                    11.7.3. Product Benchmarking
                    11.7.4. Recent Development
              11.8. Pfizer Inc.
                    11.8.1. Company Overview
                    11.8.2. Financial Performance
                    11.8.3. Product Benchmarking
                    11.8.4. Recent Development
              11.9. Regeneron Pharmaceuticals, Inc.
                    11.9.1. Company Overview
                    11.9.2. Financial Performance
                    11.9.3. Product Benchmarking
                    11.9.4. Recent Development
              11.10. Roche Holdings AG (including its subsidiary, Genentech)
                    11.10.1. Company Overview
                    11.10.2. Financial Performance
                    11.10.3. Product Benchmarking
                    11.10.4. Recent Development
              11.11. Takeda Pharmaceutical Company Limited
                    11.11.1. Company Overview
                    11.11.2. Financial Performance
                    11.11.3. Product Benchmarking
                    11.11.4. Recent Development
              11.12. Teva Pharmaceutical Industries Ltd.
                    11.12.1. Company Overview
                    11.12.2. Financial Performance
                    11.12.3. Product Benchmarking
                    11.12.4. Recent Development

List of Tables

Table 1 Global Myasthenia Gravis Disease Treatment Market, by Drug Class, by Region, 2019-2032 (USD Billion)
Table 2 Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
Table 3 Global Myasthenia Gravis Disease Treatment Market, by Treatment, by Region, 2019-2032 (USD Billion)
Table 4 Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
Table 5 Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
Table 6 North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 7 North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 8 North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 9 North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 10 U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 11 U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 12 U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 13 U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 14 Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 15 Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 16 Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 17 Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 18 Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 19 Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 20 Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 21 Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 22 Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 23 Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 24 Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 25 Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 26 France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 27 France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 28 France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 29 France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 30 UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 31 UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 32 UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 33 UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 34 Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 35 Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 36 Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 37 Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 38 Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 39 Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 40 Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 41 Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 42 Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 43 Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 44 Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 45 Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 46 Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 47 Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 48 Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 49 Russia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 50 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 51 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 52 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 53 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 54 China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 55 China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 56 China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 57 China: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 58 Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 59 Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 60 Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 61 Japan: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 62 India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 63 India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 64 India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 65 India: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 66 Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 67 Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 68 Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 69 Indonesia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 70 Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 71 Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 72 Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 73 Malaysia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 74 South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 75 South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 76 South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 77 South Korea: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 78 Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 79 Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 80 Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 81 Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 82 Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 83 Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 84 Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 85 Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 86 Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 87 Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 88 Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 89 Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 90 Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 91 Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 92 Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 93 Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 94 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 95 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 96 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 97 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 98 UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 99 UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 100 UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 101 UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 102 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 103 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 104 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 105 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 106 South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 107 South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 108 South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 109 South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 110 Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 111 Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 112 Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 113 Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

Figure 1. Global Myasthenia Gravis Disease Treatment Market, 2019-2032 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
Figure 4. Market by Geography
Figure 5. Porter’s Five Forces
Figure 6. Market by Drug Class
Figure 7. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2021 & 2030 (USD Billion)
Figure 8. Market by Distribution Channel
Figure 9. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2021 & 2030 (USD Billion)
Figure 10. Market by Diagnosis
Figure 11. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2021 & 2030 (USD Billion)
Figure 12. Market by Treatment
Figure 13. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2021 & 2030 (USD Billion)

Report Scope

Myasthenia Gravis Disease Treatment Market, Drug Class Outlook (Revenue - USD Billion, 2019-2032)

IVIg
Monoclonal Antibodies
Immunosuppressants
Cholinesterase Inhibitors
Corticosteroids

Myasthenia Gravis Disease Treatment Market, Diagnosis Outlook (Revenue - USD Billion, 2019-2032)

Blood Tests
Electrodiagnosis
Edrophonium Test

Myasthenia Gravis Disease Treatment Market, Treatment Outlook (Revenue - USD Billion, 2019-2032)

Surgery
Medication
HSCT

Myasthenia Gravis Disease Treatment Market, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Myasthenia Gravis Disease Treatment Market, Regional Outlook (Revenue - USD Billion, 2019-2032)

North America
- Drug Class Outlook
  - IVIg
  - Monoclonal Antibodies
  - Immunosuppressants
  - Cholinesterase Inhibitors
  - Corticosteroids
- Diagnosis Outlook
  - Blood Tests
  - Electrodiagnosis
  - Edrophonium Test
- Treatment Outlook
  - Surgery
  - Medication
  - HSCT
  - Others
- Distribution Channel Outlook
  - Online Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies
Europe
- Drug Class Outlook
  - IVIg
  - Monoclonal Antibodies
  - Immunosuppressants
  - Cholinesterase Inhibitors
  - Corticosteroids
- Diagnosis Outlook
  - Blood Tests
  - Electrodiagnosis
  - Edrophonium Test
- Treatment Outlook
  - Surgery
  - Medication
  - HSCT
  - Others
- Distribution Channel Outlook
  - Online Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies
Asia Pacific
- Drug Class Outlook
  - IVIg
  - Monoclonal Antibodies
  - Immunosuppressants
  - Cholinesterase Inhibitors
  - Corticosteroids
- Diagnosis Outlook
  - Blood Tests
  - Electrodiagnosis
  - Edrophonium Test
- Treatment Outlook
  - Surgery
  - Medication
  - HSCT
  - Others
- Distribution Channel Outlook
  - Online Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies
Latin America
- Drug Class Outlook
  - IVIg
  - Monoclonal Antibodies
  - Immunosuppressants
  - Cholinesterase Inhibitors
  - Corticosteroids
- Diagnosis Outlook
  - Blood Tests
  - Electrodiagnosis
  - Edrophonium Test
- Treatment Outlook
  - Surgery
  - Medication
  - HSCT
  - Others
- Distribution Channel Outlook
  - Online Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies
Middle East & Africa
- Drug Class Outlook
  - IVIg
  - Monoclonal Antibodies
  - Immunosuppressants
  - Cholinesterase Inhibitors
  - Corticosteroids
- Diagnosis Outlook
  - Blood Tests
  - Electrodiagnosis
  - Edrophonium Test
- Treatment Outlook
  - Surgery
  - Medication
  - HSCT
  - Others
- Distribution Channel Outlook
  - Online Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies

Qualitative Analysis

Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL Analysis
- Value Chain Analysis
- Key market opportunities prioritized
Competitive landscape
- Overview
- Financials
- Distribution Channel benchmarking
- Latest strategic developments
- Price Trend Analysis

Quantitative Analysis

Market size, estimates, and forecasts from 2019-2032
Market size and revenue estimates for distribution channel up to 2032
Market revenue estimates for drug class up to 2032
Market revenue estimates for diagnosis up to 2032
Market revenue estimates for treatment up to 2032
Regional market size and forecast up to 2032
Company financials

Research Methodology | Research Techniques of Polaris Market Research

Request for Sample

By using this form you agree with the storage and handling of your data by this website.

License and Pricing

Single User - $ 4250

Multi Users (Up to 20 User) - $ 5250

Enterprise License - $ 6250

Purchase Report Sections

Regional analysis
Segmentation analysis
Industry outlook
Competitive landscape

Request for Discount Pricing

Connect with experts

Speak to Analyst Request for Customization